1225P The progression-free survival of the first-line EGFR-TKI is a strong prognosticator of the second-line osimertinib in non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation: A real-world study
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI